Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial

BACKGROUND: The ICON6 trial showed that cediranib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, improved clinical outcomes for patients with platinum‐sensitive relapsed ovarian cancer when it was used with chemotherapy and was continued as maintenance therapy. This...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Stark, Dan P., Cook, Adrian, Brown, Julia M., Brundage, Michael D., Embleton, Andrew C., Kaplan, Richard S., Raja, Fharat A., Swart, Ann Marie W., Velikova, Galina, Qian, Wendi, Ledermann, Jonathan A.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5516140/
https://ncbi.nlm.nih.gov/pubmed/28339098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30657
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados